HI
IRWD icon

HBK Investments’s Ironwood Pharmaceuticals IRWD Stock Holding History

HBK Investments’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,500
Closed -$120K – 969
2020
Q4 		$120K Buy
+10,500
New +$115K ﹤0.01% 669

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

HBK Investments's IRWD Position: Q2 2019 in Review

HBK Investments sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2019, closing a stake of 268,769 shares — an estimated $3.01M sold.

HBK Investments first reported a position in IRWD in Q2 2013 and held it in 3 quarters. The position peaked at $3.05M in Q1 2019. 152 funds tracked by Wall St. Rank hold IRWD as of Q2 2019.

  • HBK Investments reported no remaining Ironwood Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • HBK Investments sold 268,769 Ironwood Pharmaceuticals shares in Q2 2019, an estimated $3.01M.
  • HBK Investments first reported a position in Ironwood Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • HBK Investments's Ironwood Pharmaceuticals position peaked at $3.05M in Q1 2019.
  • 152 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.